CN-121992098-A - Diabetes and SNP locus and kit related to combined cognitive function injury thereof

Abstract

The invention discloses a SNP locus and a kit related to diabetes and combined cognitive function injury thereof, belongs to the technical field of SNP detection, and particularly relates to a SNP locus and a kit related to diabetes and combined cognitive function injury thereof, wherein the kit comprises at least one component of amplification primers, modified polyamide ester materials and modified magnetic beads for detecting SNP molecular markers of ELAVL1 genes. The SNP molecular markers of the ELAVL1 gene comprise at least one SNP molecular marker of rs12985234, rs14394, rs35986520 and rs 10402477. The detection reagent provided by the invention can effectively and remarkably improve the amplification yield and specificity of PCR amplification and improve the PCR effect, thereby optimizing the detection effect of SNP loci.

Inventors

• DONG YIN
• LI XI
• ZHANG GAOFENG
• GUO ANQI

Assignees

• 玉环市人民医院(玉环市人民医院健共体集团)

Dates

Publication Date

20260508

Application Date

20260310

Claims (10)

1. 1. The application of the reagent for detecting the SNP locus related to diabetes and the combined cognitive function injury thereof in preparing the reagent for predicting diabetes and the combined cognitive function injury thereof is characterized in that the SNP locus is at least one locus of rs12985234, rs14394, rs35986520 and rs 10402477.
2. 2. The method according to claim 1, wherein the reagent for detecting SNP loci associated with diabetes and combined cognitive impairment is selected from one or more of DNA microarray or chip, specific PCR primer or probe, and targeted high throughput sequencing reagent for detecting genetic marker combinations of SNP loci.
3. 3. The method of claim 1 or 2, wherein the nucleotide sequence of the primer before amplification for detecting rs12985234 is shown as SEQ ID No.1, the nucleotide sequence of the primer after amplification is shown as SEQ ID No.2, and/or The nucleotide sequence of the amplification front primer of rs14394 is shown as SEQ ID No.3, the nucleotide sequence of the amplification rear primer is shown as SEQ ID No.4, and/or The nucleotide sequence of the amplification front primer of rs35986520 is shown as SEQ ID No.5, the nucleotide sequence of the amplification rear primer is shown as SEQ ID No.6, and/or The nucleotide sequence of the amplified front primer of rs10402477 is shown as SEQ ID No.7, and the nucleotide sequence of the amplified rear primer is shown as SEQ ID No. 8.
4. 4. The detection kit for the SNP loci related to diabetes and the combined cognitive impairment thereof is characterized by comprising the following components: amplification primers for detecting at least one locus of rs12985234, rs14394, rs35986520, rs10402477 of the ELAVL1 gene; The nucleotide sequence of the amplification front primer of rs12985234 is shown as SEQ ID No.1, and the nucleotide sequence of the amplification rear primer is shown as SEQ ID No. 2; The nucleotide sequence of the amplification front primer of rs14394 is shown as SEQ ID No.3, and the nucleotide sequence of the amplification rear primer is shown as SEQ ID No. 4; the nucleotide sequence of the amplification front primer of rs35986520 is shown as SEQ ID No.5, and the nucleotide sequence of the amplification rear primer is shown as SEQ ID No. 6; The nucleotide sequence of the amplification front primer of rs10402477 is shown as SEQ ID No.7, and the nucleotide sequence of the amplification rear primer is shown as SEQ ID No. 8.
5. 5. The test kit of claim 4, further comprising a modified polyesteramide material.
6. 6. The detection kit according to claim 5, wherein the preparation method of the modified polyesteramide material comprises dissolving diethylenetriamine in methanol under the conditions of low temperature and nitrogen atmosphere, adding ethylene glycol diacrylate, stirring and mixing uniformly for normal temperature reaction, performing reduced pressure rotary evaporation, and adding 2-octenyl succinic anhydride for reduced pressure reaction to obtain the modified polyesteramide material.
7. 7. The test kit of claim 6, wherein the diethylenetriamine and methanol are used in a ratio of 1mol:50-200mL.
8. 8. The test kit of claim 6, wherein the molar ratio of diethylenetriamine to ethylene glycol diacrylate is 1:0.3-0.5.
9. 9. The test kit of claim 6, wherein the molar ratio of diethylenetriamine to 2-octenyl succinic anhydride is 1:1-3.
10. 10. The test kit according to claim 6, wherein the reduced pressure reaction temperature is 140-160 ℃.

Description

Diabetes and SNP locus and kit related to combined cognitive function injury thereof Technical Field The invention relates to the technical field of SNP detection, in particular to a SNP locus and a kit related to diabetes and combined cognitive function injury thereof. Background Type 2 diabetes mellitus (Type 2 diabetes, T2D) is one of the most common metabolic diseases worldwide, and its pathological features include not only persistent hyperglycemia and "three more and one less" typical clinical manifestations, but also various serious systemic diseases such as cardiovascular and cerebrovascular diseases, diabetic nephropathy, retinopathy, etc. are often accompanied. At the same time, T2D patients are associated with complications of mood cognitive disorders such as depression, anxiety and dementia, which lead to a significant reduction in their quality of life and a significant increase in the risk of disability and mortality. In the context of an increased trend of global population aging and inadequate social care resources, T2D patients who incorporate emotional cognitive impairment face more serious health challenges. Although some progress has been made in the prevention and diagnosis of T2D at present, the pathogenesis of the disease is still not fully elucidated, and the existing early screening and intervention means still have limitations in terms of accuracy, especially lack of reliable biomarkers capable of simultaneously early warning T2D and its emotional cognitive impairment, which has become a critical problem to be solved urgently in the clinical and public health fields. The role of RNA-binding proteins in the regulation of metabolic and neurological diseases is of increasing interest. Wherein, human antigen R (HuR) coded by ELAVL1 gene is taken as an important RNA binding protein and widely participates in cell proliferation, differentiation, stress reaction and mRNA stability regulation, previous researches indicate that HuR is up-regulated in diabetic nephropathy, retinopathy and other complications and promotes disease progression through stabilizing related factor mRNA, and simultaneously, huR plays a key role in neural development and plasticity, and expression change of the HuR can influence neuron functions and depression-like behaviors. Single Nucleotide Polymorphisms (SNPs) have been shown to be associated with susceptibility to a variety of diseases as a common form of genetic variation. Currently, whole genome association studies (GWAS) have identified hundreds of T2D susceptibility sites, but systematic studies on the HuR gene SNPs in T2D and its mood cognitive disorders remain very limited. Earlier studies show that part of SNPs (such as rs12983784 and the like) of the HuR gene are related to cancer risk, and mutation rates of the SNPs of the HuR gene in a T2D patient are abnormal, which suggests that the genetic variation of the HuR gene may be involved in the occurrence and development of T2D and emotion cognitive disorder thereof, but the specific action mechanism and clinical application value of the genetic variation of the HuR gene are not clear. Although the prior art has found a number of SNP markers associated with T2D risk, no research system has yet explored the feasibility of HuR gene SNPs, especially their association with emotional cognitive impairment, as T2D early screening and intervention targets. Therefore, how to provide a biomarker based on the SNPs of the HuR gene and a detection technical means thereof so as to fill the application blank of the biomarker in the prediction, diagnosis and prevention of T2D and emotion cognitive disorder thereof, and the biomarker becomes a scientific problem to be solved urgently at present. Disclosure of Invention The invention aims to provide SNP loci and a kit related to diabetes and combined cognitive function impairment thereof, which not only provide SNP molecular markers related to diabetes and combined cognitive function impairment based on ELAVL1 genes, but also obviously improve the amplification yield and specificity of PCR amplification by optimizing key components of a detection kit thereof, thereby effectively improving PCR reaction performance and realizing efficient and accurate detection of target SNP loci. The technical scheme adopted by the invention for achieving the purpose is as follows: Application of reagent for detecting SNP locus related to diabetes and combined cognitive function injury thereof in preparation of reagent for predicting diabetes and combined cognitive function injury thereof, wherein the SNP locus is at least one locus of rs12985234, rs14394, rs35986520 and rs 10402477. Preferably, the reagent for detecting diabetes and the SNP locus related to the combined cognitive function impairment is selected from one or more of DNA microarrays or chips for detecting genetic marker combinations of the SNP locus, specific PCR primers or probes and targeted high-throughput sequencing reage